|
COURSE DESCRIPTION
Target Audience
This activity is aimed at physicians,
infectious disease specialists, surgeons,
and other health professionals involved
and/or interested in the management
of invasive fungal infections within
immunosuppressed populations. No special
skills other than basic knowledge
of microbiology and general internal
medicine are required for successful
participation in this activity
Educational Objectives
After successfully completing this
continuing medical education program
participants should be able to:
- Understand diagnostic challenges
in invasive fungal infections
- Incorporate updated efficacy
and safety data on novel antifungal
agents into current management practices
- Optimally manage prophylaxis in
immunocompromised patients at high
risk for invasive fungal infections
Continuing Medical Education
for Physicians
Imedex®, Inc. is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
Imedex®, Inc. designates
this educational activity for a maximum
of 1.5 category 1 credits toward the
AMA Physician’s Recognition Award.
Each physician should claim only those
credits that he/she actually spent
in the activity.
Credits will be awarded upon completion
and submission of the self-assessment
questions, evaluation form, and CME
credit request form to:
Imedex®, Inc.
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1 (770) 751 7334
Deadline for CME Credit
submission: May 15, 2007
Unapproved and Investigational
Uses of Drugs and Devices
This webcast and CD-ROM may contain
information about experimental and
other uses of drugs or devices that
are not currently approved by the
Food and Drug Administration (FDA)
and/or other national regulatory agencies
in the United States and other countries.
Participants in the United States
are encouraged to consult the FDA-approved
product labeling for any drug or device
mentioned in this program before use.
Participants from other countries
should consult with their respective
regulatory authorities.
The opinions expressed in this webcast
and CD-ROM are the opinions of the
authors and do not necessarily reflect
the opinions of Imedex®,
Inc. or Schering Plough.
Program Organizer
Imedex®, Inc.
4325 Alexander Drive
Alpharetta, GA 30022
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Disclosure of Financial Interests
As an accredited provider of Continuing
Medical Education, Imedex, Inc. is
required to ask speakers to disclose
any real or apparent conflict of interest
they may have as related to the contents
of their presentation(s). The existence
of commercial or financial interests
of speakers related to the subject
matter of their presentation(s) should
not be construed as implying bias
or decreasing the value of their presentation(s).
However, disclosure should help participants
form their own judgments.
All speakers were independently selected
by the organizing committee. Those
speakers who disclosed affiliations
or financial interests with the commercial
organizations involved with products,
to which they may refer, are listed
below.
1=grant/research support
2=consultant
3=speaker’s bureau
4=stock shareholder
5=other support
The following speakers have reported
an affiliation with non-supporting
companies of this webcast & CD-ROM:
- John R. Perfect, MD - Astellas
Pharma US, Inc.1, 2, 3,
Enzon1, 2, 3, Merck1,
2, 3, Pfizer1, 2, 3
- Jack D. Sobel, MD - Astellas Pharma
US, Inc.1, Johnson &
Johnson Pharmaceuticals1,
Merck1,2,3,4,5, Pfizer3,5,
Presutti Laboratories, LLC2
The following speaker has reported
an affiliation with the supporter
of this webcast & CD-ROM:
The following speaker does not report
any affiliation:
Imedex®, Inc. is an independent
provider of Continuing Medical Education.
Imedex, Inc. has no proprietary or
financial interest in medical or healthcare
products over which the FDA has regulatory
authority.
©2006 Imedex®, Inc. All
rights reserved. Reproduction in whole
or part is prohibited without prior
written consent from Imedex and contributing
faculty.
|
